clindamycin ** 7(S)-chloro-7-deoxylincomycin ** chlolincocin ** chlorlincocin ** U-21251 ** Translations

Environmental Fate - Ecotoxicology - Human Health - A to Z Index - Home

GENERAL INFORMATION

Description: Used primarily to treat infections caused by susceptible anaerobic bacteria and is effective against bacteria that infect the skin, oral cavity, bone and respiratory tract

Introduction: -

Examples of species treated: Dogs, Cats

General status:

Veterinary substance type	Antibiotic, Antibacterial, Medicinal drug
Substance group	Lincosamide
Substance origin	Semi-synthetic
Mode of action	A bacterial protein synthesis inhibitor that works by inhibiting ribosomal translocation
Molecular targets	50S ribosomal protein L10, antagonist 23S rRNA, antagonist
CAS RN	18323-44-9
EC number	242-209-1
CIPAC number	-
US EPA chemical code	-
ATCvet Code	QJ01FF01
Therapeutic Class	Antiinfectants for systemic use: Antibacterials for systemic use
Controlled Drug?	No
Regulation 37/2010 MRL Classification	No data
Chemical formula	C18H33ClN2O5S
SMILES	[C@H]1([C@H](NC(=O)[C@@H]2C[C@H](CN2C)CCC)[C@H](C)Cl)O[C@@H]([C@@H]([C@H]([C@H]1O)O)O)SC
International Chemical Identifier (InChI)	InChI=1S/C18H33ClN2O5S/c1-5-6-10-7-11(21(3)8-10)17(25)20-12(9(2)19)16-14(23)13(22)15(24)18(26-16)27-4/h9-16,18,22-24H,5-8H2,1-4H3,(H,20,25)/t9-,10+,11-,12?,13-,14+,15+,16+,18+/m0/s1
Structure diagram/image available?	Yes
Molecular mass (g mol-1)	424.98
IUPAC Name	(2S,4R)-N-{2-chloro-1-[(2R,3R,4S,5R,6R)-3,4,5-trihydroxy-6-(methylsulfanyl)oxan-2-yl]propyl}-1-methyl-4-propylpyrrolidine-2-carboxamide
CAS Name	methyl-7-chloro-6,7,8-trideoxy-6-[[[(2S,4R)-1-methyl-4-propyl-2-pyrrolidinyl]carbonyl]amino]-1-thio--threo-a-D-galacto-octopyranoside
Other status information	-
Physical state	Yellow, amorphous solid as parent, white liquid as phosphate
Related substances & organisms	lincomycin pirlimycin hydrochloride

Formulations:

Property	Product	Manufacturer	Authorisation Route	UK Legal Class
Example products using this active	Clindacyl 300 mg tablets	Vetoquinol UK Ltd	UK National authorisation (IC)	Prescription only medicine to be authorised by a veterinarian (POM-V)
	Clindacyl 75 mg tablets	Vetoquinol UK Ltd	UK National authorisation (IC)	Prescription only medicine to be authorised by a veterinarian (POM-V)
	Antirobe capsules 150mg	Pfizer Ltd	UK National authorisation	Prescription only medicine to be authorised by a veterinarian (POM-V)
	Clinacin 150mg tablets	Chanelle Animal health	UK National authorisation	Prescription only medicine to be authorised by a veterinarian (POM-V)
Formulation and application details	Usually supplied in tablet or capsule form for oral administration.

ENVIRONMENTAL FATE

Property		Value	Source/Quality Score/Other Information	Interpretation
Solubility - In water at 20oC (mg l-1)		30.6	V3	Low
Solubility - In organic solvents at 20oC (mg l-1)		-	-	-
Melting Point (oC)		141	L3	-
Boiling Point (oC)		Decomposes before boiling	E3	-
Degradation point (oC)		-	-	-
Flashpoint (oC)		334	Q3	-
Octanol-water partition coefficient at pH 7, 20oC	P	1.45 X 1002	Calculated	-
	Log P	2.16	V3	Low
Bulk density (g ml-1)/Specific gravity		1.29	Q3	-
Dissociation constant (pKa) at 25oC		-	-	-
		Note:
Vapour pressure at 25oC (mPa)		7.02 X 10-12	V3	Non-volatile
Henry's law constant at 25oC (Pa m3 mol-1)		-	-	-
Henry's law constant at 20oC (dimensionless)		4.00 X 10-17	Calculated	Non-volatile
GUS leaching potential index		-	-	-
Maximum UV-vis absorption L mol-1 cm-1		-	-	-
Surface tension (mN m-1)		-	-	-
Refractive Index		-	-	-

Degradation:

Property		Value	Source/Quality Score/Other Information	Interpretation
Soil degradation (days) (aerobic)	DT50 (typical)	-	-	-
	DT50 (lab at 20oC)	-	-	-
	DT50 (field)	-	-	-
	DT90 (lab at 20oC)	-	-	-
	DT90 (field)	-	-	-
	Note:	-
Manure DT50 (days)		-	-	-
Aqueous photolysis DT50 (days) at pH 7	Value	-	-	-
	Note	-
Aqueous hydrolysis DT50 (days) at 20oC and pH 7	Value	Stable	CA3	Very persistent
	Note	Hydrolysis not expected under environmental conditions
Water-Sediment DT50 (days)		-	-	-
Water phase only DT50 (days)		-	-	-

Soil adsorption and mobility:

Property		Value	Source/Quality Score/Other Information	Interpretation
Linear	Kd	-	CA2	Moderately mobile
	Koc	360
	Notes and range	Estimated
Freundlich	Kf	-	-	-
	Kfoc	-
	1/n	-
	Notes and range	-
pH sensitivity		-

ECOTOXICOLOGY

Property		Value	Source/Quality Score/Other Information	Interpretation
Bio-concentration factor	BCF	-	-	-
	CT50 (days)	-		-
Bioaccumulation potential		-	Calculated	Low
Mammals - Acute oral LD50 (mg kg-1)		1832	E3 Rat	Moderate
Mammals - Short term dietary NOEL	(mg kg-1)	-	-	-
	(ppm diet)	-		-
Birds - Acute LD50 (mg kg-1)		-	-	-
Birds - Short term dietary (LC50/LD50)		-	-	-
Fish - Acute 96 hour LC50 (mg l-1)		-	-	-
Fish - Chronic 21 day NOEC (mg l-1)		-	-	-
Aquatic invertebrates - Acute 48 hour EC50 (mg l-1)		-	-	-
Aquatic invertebrates - Chronic 21 day NOEC (mg l-1)		-	-	-
Aquatic crustaceans - Acute 96 hour LC50 (mg l-1)		-	-	-
Sediment dwelling organisms - Acute 96 hour LC50 (mg l-1)		-	-	-
Sediment dwelling organisms - Chronic 28 day NOEC, static, water (mg l-1)		-	-	-
Sediment dwelling organisms - Chronic 28 day NOEC, sediment (mg kg-1)		-	-	-
Aquatic plants - Acute 7 day EC50, biomass (mg l-1)		-	-	-
Algae - Acute 72 hour EC50, growth (mg l-1)		-	-	-
Algae - Chronic 96 hour NOEC, growth (mg l-1)		-	-	-
Honeybees - Acute 48 hour LD50 (µg bee-1)		-	-	-
Earthworms - Acute 14 day LC50 (mg kg-1)		-	-	-
Earthworms - Chronic 14 day NOEC, reproduction (mg kg-1)		-	-	-
Other soil macro-organisms - e.g. Collembola	LR50product ha EC50product ha NOECproduct ha % Effect	-	-	-
Other arthropod (1)	LR50 g ha-1	-	-	-
	% Effect	-	-	-
Other arthropod (2)	LR50 g ha-1	-	-	-
	% Effect	-	-	-
Soil micro-organisms		-	-	-
Mesocosm study data	NOEAEC mg l-1	-	-	-
	NOEAEC mg l-1	-	-	-

HUMAN HEALTH AND PROTECTION

General:

Property		Value	Source/Quality Score/Other Information	Interpretation
Mammals - Acute oral LD50 (mg kg-1)		1832	E3 Rat	Moderate
Mammals - Dermal LD50 (mg kg-1 body weight)		-	-	-
Mammals - Inhalation LC50 (mg l-1)		-	-	-
Other Mammal toxicity endpoints		Subcutaneous LD50 = 2618 mg kg-1	V3 Rat	-
ADI - Acceptable Daily Intake (mg kg-1bw day-1)		-	-	-
ARfD - Acute Reference Dose (mg kg-1bw day-1)		-	-	-
AOEL - Acceptable Operator Exposure Level - Systemic (mg kg-1bw day-1)		-	-	-
Dermal penetration studies (%)		-	-	-
Dangerous Substances Directive 76/464		-	-	-
Exposure Limits		-	-	-
Exposure Routes	Public	-
	Occupational	-
Elimination route and rate		Excreted mainly in bile with around 20% eliminated in the faeces and urine. Secreted in breast milk.	F4	-

Health issues:

Carcinogen	Mutagen	Endocrine disrupter	Reproduction / development effects	Acetyl cholinesterase inhibitor	Neurotoxicant	Respiratory tract irritant	Skin irritant	Eye irritant
		-		-	-	-
General human health issues		[May cause severe intestinal problems including diarrhea, nausea & colitis]

: Yes, known to cause a problem
: No, known not to cause a problem
: Possibly, status not identified
- : No data

Handling issues:

Property		Value	Source/Quality Score/Other Information	Interpretation
General		[In a fire may decompose and produce irritating vapors and toxic compounds]
EC Risk Classification		[Xn- Harmful: R22], [Xi - Irritant: R36, R38]
EC Safety Classification		S36
WHO Classification		None - not a ppp	-	-
US EPA Classification (formulation)		-	-	-
UN Number		-
Waste disposal & packaging		-

TRANSLATIONS